Summary of Xencor Fireside Chat Company Overview - **Xencor** is a biotechnology company specializing in protein engineering technology, particularly in creating antibodies with best-in-class properties. The company has established a broad pipeline in oncology and autoimmune diseases, focusing on proprietary drug development, especially in solid tumors and T-cell engagers [2][3]. Key Milestones and Focus Areas - Xencor aims to define dosing regimens and efficacy profiles for its lead solid tumor T-cell engagers, **XmAb819** and **XmAb541**, with pivotal trials expected to initiate in 2027 [3][6]. - The company is also focused on developing a **TL1A bispecific** and long-acting monospecific antibody, with key readouts anticipated to enhance value creation in late-phase development [5]. XmAb819 Development Insights - **XmAb819** targets ENPP3-expressing tumor cells while sparing normal tissues, showing a promising 25% response rate in heavily pretreated renal cell carcinoma patients [7][12]. - The design of XmAb819 aims to avoid impacting healthy tissues, with early clinical data indicating excellent tolerability after the initial priming doses [7][11]. - The company is exploring the potential to move XmAb819 into earlier lines of therapy, leveraging its novel mechanism and high ENPP3 expression in clear cell renal cell carcinoma [13][19]. Clinical Development Strategy - Xencor is conducting a sub-study to evaluate XmAb819's monotherapy potential in TKI-naive patients, which could significantly impact the treatment landscape [22]. - The company is also assessing combination therapy opportunities, particularly with PD-1 inhibitors and HIF-2 alpha, to address the unmet needs in renal cell carcinoma [31][32]. XmAb541 and Other Oncology Programs - Initial data from the **XmAb541** program in ovarian and germ cell tumors is being evaluated to determine its potential as a significant opportunity or a niche product [43][51]. - The company is enrolling patients across various tumor types, including papillary renal cell and colorectal cancer, to establish a robust data set for future strategic decisions [57]. Immunology Focus - Xencor's **TL1A** program, particularly **XmAb942**, is designed to have a long half-life and durable suppression of TL1A levels, with a phase 2b global study planned to establish the phase 3 dose [61][62]. - The company aims to position its TL1A program as best-in-class by focusing on efficacy, durability, and dosing convenience, with a target of Q12 week dosing in maintenance [73]. Market Opportunities and Strategic Considerations - Xencor anticipates significant market opportunities in both oncology and immunology, with the potential to capture substantial patient populations [29][82]. - The company is considering partnerships but currently views its assets as capable of being developed independently [60]. Conclusion - Xencor is strategically positioned in the biotechnology sector with a focus on innovative therapies for oncology and immunology. The company is actively advancing its clinical programs and exploring various avenues for maximizing the utility of its drug candidates in the market [1][84].

Summary of Xencor Conference Call Company Overview - **Company**: Xencor (NasdaqGM:XNCR) - **Focus**: Protein and antibody engineering, developing proprietary monoclonal and bispecific antibodies for oncology and autoimmune diseases - **Goal**: To become a fully integrated company by advancing its own programs through clinical trials to market [4][5] Key Priorities - **Clinical Development**: Focus on advancing internal clinical programs, particularly in oncology and autoimmune diseases - **Oncology Programs**: - XmAb819 for renal cell carcinoma - XmAb541 for claudin-6-positive tumors - **Autoimmune Programs**: Launching additional studies, including XmAb412 targeting TL1A and IL-23p19 [6][7] XmAb819 Program Highlights - **Mechanism**: Bispecific antibody targeting ENPP3 and CD3, designed for high engagement and cytotoxicity in tumor cells while minimizing toxicity in normal tissues - **Recent Data**: - 25% objective response rate in heavily pretreated patients with clear cell renal cell carcinoma - Median of 4 prior lines of treatment, with 100% exposure to immune-oncology (IO) and tyrosine kinase inhibitors (TKIs) [11][20] - **Safety Profile**: Dominated by cytokine release syndrome (CRS) and rash, manageable for long-term use [12] - **Future Plans**: - Pivotal trials expected to start in 2027 - Exploring monotherapy potential in earlier treatment lines and other tumor types, including papillary renal cell carcinoma and non-small cell lung cancer [16][18] XmAb541 Program Highlights - **Current Status**: Dose escalation ongoing with a 30% response rate observed in a basket study of germ cell tumors and ovarian cancer - **Future Plans**: Expected to lock down the recommended phase 3 dose later this year [39][40] Competitive Landscape - **XmAb819**: Limited competition in clear cell renal cell carcinoma, with a focus on novel mechanisms and monotherapy activity [31][32] - **XmAb541**: Dense competitive landscape in ovarian cancer, but potential to differentiate as a first-in-class T-cell engager [48] Immunology Programs - **XmAb942 and XmAb412**: Targeting TL1A for autoimmune diseases, with a focus on high potency and long half-life to maximize exposure - **Upcoming Updates**: Full results from phase 1 studies expected at DDW, with a focus on the potential for a long-acting TL1A therapy [49][54] Business Development Strategy - **Focus**: Advancing the pipeline, with potential partnerships to enhance resource capabilities when necessary [58] Market Opportunity - **XmAb819**: Significant market potential in late-line renal cell carcinoma and expansion into other tumor types could double market opportunities [24][26] - **XmAb541**: Addressing high unmet needs in germ cell tumors and ovarian cancer, with a strategic approach to market entry based on clinical data [44] Conclusion - Xencor is positioned to leverage its innovative antibody engineering capabilities to address significant unmet needs in oncology and autoimmune diseases, with promising clinical data supporting its lead programs. The company is focused on advancing its pipeline while exploring strategic partnerships to enhance its development efforts.

Summary of Xencor's Presentation at TD Cowen's 46th Annual Healthcare Conference Company Overview - **Company**: Xencor - **Industry**: Biotechnology - **Focus**: Clinical stage biotech company specializing in protein engineering to develop therapies for oncology and autoimmune diseases [3][4] Core Points and Arguments Clinical Strategy and Pipeline - Xencor is focusing on advancing its clinical strategy starting in 2024, aiming to bring programs into Phase 1 and Phase 2 trials, with a goal of commercializing successful candidates [5] - The company has a strong financial position with over **$600 million** in cash, allowing for flexibility in drug development decisions [6] - Xencor's current clinical portfolio includes two lead oncology programs: **XmAb819** and **XmAb541**, both T-cell engagers targeting specific antigens on tumor cells [7] Oncology Programs - **XmAb819**: - Focused on clear cell renal cell carcinoma, with promising initial data presented at the Triple Oncology Meeting [8] - Plans for pivotal development in **2027** and expansion into additional tumor types [15] - **XmAb541**: - Targeting Claudin-6 in gynecologic tumors, with updates expected later in the year [9][15] Autoimmune Programs - **XmAb942**: - A global Phase IIb study in ulcerative colitis, aiming to provide a best-in-class biologic therapy for patients with high unmet needs [10] - Expected to present final results from a healthy volunteer study at the Digestive Disease Week (DDW) [24] - **XmAb412**: - A bispecific antibody targeting TL1A and IL-23p19, with first-in-human studies starting in the latter half of **2026** [11][12] - **Plamotamab**: - A CD20 T-cell engager in rheumatoid arthritis, with ongoing studies to evaluate its effectiveness compared to traditional monoclonal antibodies [47] - **XmAb657**: - Aiming to mimic CAR T-cell therapy for severe autoimmune diseases, with a focus on delivering durable clinical remission [55] Important Insights - Xencor's protein engineering platform allows for the development of unique therapies that can potentially outperform existing treatments in both oncology and autoimmune diseases [18] - The company emphasizes the importance of understanding the clinical landscape and patient needs to guide its drug development strategy [36] - Xencor's partnerships have provided meaningful royalties and insights that enhance its clinical development capabilities [19] Future Catalysts - Updates on XmAb819 and XmAb541 are expected in the latter half of the year, with pivotal studies planned for **2027** [15][16] - The company is also preparing for the first-in-human study of XmAb412, which is anticipated to provide significant insights into its clinical applicability [27] Conclusion Xencor is positioned to make significant advancements in the biotechnology sector with its innovative drug development strategy, focusing on both oncology and autoimmune diseases. The company is leveraging its strong financial position and unique protein engineering capabilities to address unmet medical needs and drive future growth [20]

Summary of Zencore Conference Call Company Overview - **Company**: Zencore - **Event**: Cantor Global Healthcare Conference - **Date**: September 04, 2025 Key Points Current State and Strategy - Zencore is focused on developing drugs for severe diseases using its XmAb Protein Engineering Platform, targeting unmet needs in both oncology and autoimmune diseases [3][4] - The company is advancing into immunology indications, building on its core oncology expertise [2][3] Bispecific T Cell Engager Program - The XmAb819 bispecific T cell engager targets ENPP3, a protein expressed in renal cell carcinoma (RCC) and other solid tumors [6][10] - Initial data from the dose escalation phase is expected to be presented at the AACR NCI EORTC meeting in October 2025 [10][18] - The program aims to provide a differentiated treatment option in a complex therapeutic landscape for RCC, where existing therapies have limitations [13][14] Clinical Landscape for RCC - Current first-line treatments for advanced clear cell RCC include PD-1 inhibitors and VEGF TKIs, with a lack of effective options for patients who progress beyond second-line therapy [13][14] - Belzutafan, a recently approved therapy, has shown a 25% response rate in heavily pretreated patients, indicating a need for more effective treatments [15][16] TL1A Asset Development - Zencore is developing TL1A as a potential best-in-class molecule for inflammatory bowel disease (IBD) and other indications [22][23] - The company is initiating a Phase 2b study in ulcerative colitis, with plans to explore additional indications like Crohn's disease [24][28] - The TL1A program is positioned to capitalize on the limitations of existing therapies, aiming for improved efficacy and patient outcomes [27][28] Bispecific Antibody Approach - Zencore is exploring bispecific antibodies targeting TL1A and IL-23, with potential applications in IBD and other autoimmune diseases [29][30] - The bispecific approach is expected to offer a safer profile and improved dosing flexibility compared to existing therapies [29][34] Future Outlook - Zencore plans to continue leveraging its engineering tools to develop novel drug candidates while focusing on clinical data generation [51][52] - The company is optimistic about the potential of its current pipeline, particularly in the context of unmet medical needs in oncology and autoimmune diseases [18][52] Additional Insights - The company acknowledges the challenges in modeling drug exposure in the gut for IBD therapies, emphasizing the need for high drug exposure to achieve desired clinical outcomes [39][42] - Zencore is committed to exploring the therapeutic potential of B cell depletion in autoimmune diseases, drawing parallels with successful oncology therapies [45][48] Conclusion - Zencore is strategically positioned to advance its innovative therapies in oncology and immunology, with a strong focus on addressing unmet medical needs through its proprietary engineering platform and clinical development programs [51][52]

Financial Data and Key Metrics Changes - The company is at a clinical inflection point with a focus on oncology and autoimmune disease programs, indicating a strategic reset and a shift towards higher probability success programs [4][5] - The Phase 2b study for the monospecific TL1a program in ulcerative colitis has commenced, with expectations for significant data generation in the coming years [6][7] Business Line Data and Key Metrics Changes - The company has three therapeutic verticals: oncology, autoimmune diseases, and a focus on protein engineering to enhance drug modalities [6][7] - XmAb942, targeting TL1a, has shown a greater than seventy-one day half-life, allowing for a Q12 week dosing schedule, which is a significant improvement over first-generation drugs [12][18] Market Data and Key Metrics Changes - The company is targeting advanced clear cell renal cell carcinoma with XmAb819, which has a high unmet need for innovative treatments [36][40] - The competitive landscape includes other companies developing TL1a and IL-23 inhibitors, with the company aiming to differentiate its products through superior potency and dosing schedules [13][21] Company Strategy and Development Direction - The company aims to leverage its protein engineering platform to create differentiated therapies that maximize patient benefits and advance the standard of care [6][7] - A strategic reset in September 2024 has set the stage for clinical data generation and regulatory approvals, with a focus on bringing the story together for investors [46][47] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical development pipeline and the potential for differentiated clinical profiles that could lead to successful commercialization [19][41] - The company is focused on efficient study designs to expedite the transition to pivotal studies and commercialization [19][33] Other Important Information - The company has initiated multiple clinical studies, including the bispecific TL1A and IL-23 program, with first-in-human studies expected in 2026 [22][24] - The company is also ramping up studies for plamotamab and XmAb657, with regulatory authorizations in progress [26][27] Q&A Session Summary Question: Can you discuss the rationale for targeting ENPP3 in CCRC patients? - The company chose ENPP3 based on internal data and third-party validation, allowing for a faster study design without preselecting patients [36][38] Question: What are the advantages of the bispecific design over combining an anti-TL1A with an IL-23? - The bispecific design allows for a synergistic effect between TL1A and IL-23, potentially leading to better clinical outcomes with a single drug delivery [21][22] Question: What is the expected timeline for initial data readout for plamotamab? - Initial data is expected towards the end of this year or early next year as the study ramps up [33] Question: How does the company plan to differentiate XmAb541 from other therapies? - The company aims to achieve a favorable safety profile and effective dosing regimen to differentiate XmAb541 from existing therapies targeting CLDN6 [44][45]

XmAb Technology and Pipeline - Xencor's XmAb platform is used to engineer antibodies with enhanced properties, focusing on oncology and autoimmune diseases[4, 9, 10] - The pipeline includes T-cell engagers and bispecific antibodies targeting various cancers and autoimmune conditions, such as IBD and rheumatoid arthritis[10, 11] - Key programs include XmAb942 (TL1A inhibitor) for IBD, Plamotamab (CD20xCD3) for rheumatoid arthritis, and XmAb819 (ENPP3 x CD3) for ccRCC[11, 12] XmAb942: Anti-TL1A Antibody for IBD - XmAb942 is designed for potent TL1A inhibition, convenient subcutaneous dosing, and extended half-life, potentially enabling Q12W maintenance dosing[31] - Phase 1 study in healthy volunteers showed a +71 day estimated half-life and dose-dependent increases in total TL1A, supporting less frequent dosing[31, 45] - Phase 1 data also showed rapid and sustained reduction of free sTL1A below the lower limit of quantification (LLOQ) for at least 16 weeks from a single dose[49] XmAb942 Clinical Development and Market Opportunity - A Phase 2 study (XENITH-UC) in ulcerative colitis is planned, with a design to maximize drug exposure and potentially achieve greater efficacy[56, 61] - The global IBD drug market is projected to exceed $23 billion by 2030, with anti-TL1A therapies expected to capture a significant portion[14, 74] - Gastroenterologist surveys indicate high expected utilization of anti-TL1A drugs, with approximately 9 out of 10 expecting to use them as first or second-line advanced therapy[74] XmAb TL1A x IL23 Bispecific Program - Xencor is developing XENP53***, a TL1A x IL23p19 bispecific antibody, with lead candidate selection and GMP production underway for a planned first-in-human study in 2026[11, 71] - Preclinical data suggests competitive functional potency for both TL1A and IL23 inhibition compared to other agents[69, 70] Financial Position - Xencor reported $706.7 million in cash, cash equivalents, and marketable debt securities as of December 31, 2024, supporting the development and expansion of the TL1A program[89]

Summary of Xencor (XNCR) Update / Briefing April 29, 2025 Company Overview - **Company**: Xencor (XNCR) - **Focus**: Development of protein engineering and drug molecules for unmet medical needs, particularly in oncology and immunology Key Industry Insights - **Industry**: Inflammatory Bowel Disease (IBD) treatment - **Current Market Need**: High unmet medical need in IBD, with existing medications achieving remission in only 10% to 20% of patients [7][8] - **Target Population**: Over 3 million individuals affected by IBD in the U.S. and Europe [7] Core Program Updates - **XmAb942**: A high potency, half-life extended anti-TL1A antibody - **Phase I Study Results**: Positive interim results indicating safety and pharmacokinetics [2][12] - **Half-Life**: Estimated at greater than 71 days, promising for convenient dosing [14] - **Dosing Schedule**: Planned Q12 week subcutaneous maintenance dosing [11][21] - **TL1A by IL-23 P19 Bispecific**: A lead candidate designed to combine two effective mechanisms of action for IBD treatment - **Development Timeline**: First in human studies expected in 2026 [58] Clinical Development Plans - **Phase II Study (ZENITH UC)**: - Focus on patients with moderately to severely active ulcerative colitis who have failed previous therapies [19][21] - Primary endpoint: Clinical remission based on modified Mayo Score at week twelve [21] - Expected to start in the second half of 2025 [61] Competitive Landscape - **Comparison with Competitors**: XmAb942 expected to provide higher drug exposure and better clinical outcomes compared to leading first-generation anti-TL1A drugs [60] - **Dosing Frequency**: Over 90% of surveyed gastroenterologists believe that XmAb942's Q12 week dosing could significantly improve patient compliance [61] Future Directions - **Combination Therapies**: Emphasis on developing a combination strategy with IL-23 and TL1A targeting to enhance efficacy [49][54] - **Market Positioning**: Xencor aims to position XmAb942 as a first or second line treatment option in advanced IBD therapy [60] Important Considerations - **Safety Profile**: No significant safety signals observed in Phase II data for competing therapies [31] - **Patient Compliance**: A more convenient dosing schedule is expected to improve patient quality of life and adherence to treatment [42][43] Conclusion - Xencor is advancing its pipeline with promising data for XmAb942 and a bispecific candidate targeting TL1A and IL-23, aiming to address significant unmet needs in IBD treatment while enhancing patient experience through improved dosing regimens and safety profiles [66]